Efficacy and safety of edaravone sublingual tablet for patients with cerebral small vessel disease-related cognitive impairment: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial

Key Points

• This trial aims to assess the efficacy and safety of edaravone sublingual tablets for cognitive impairment in cerebral small vessel disease.
• Multicentre design
• Randomised, double-blind, placebo-controlled trial
• Participants with cerebral small vessel disease-related cognitive impairment
• Trial evaluates edaravone's efficacy and safety
• Focus on cognitive impairment outcomes
• Potential new treatment strategy for cerebral small vessel disease